Cannabinol (CBN; 30 and 300 mg) effects on sleep and next-day function in insomnia disorder (‘CUPID’ study): protocol for a randomised, double-blind, placebo-controlled, cross-over, three-arm, proof-of-concept trial

Cannabinol (CBN; 30 and 300 mg) effects on sleep and next-day function in insomnia disorder (‘CUPID’ study): protocol for a randomised, double-blind, placebo-controlled, cross-over, three-arm, proof-of-concept trial

Objective Insomnia is the most prevalent sleep disorder, with few effective pharmacotherapies. Anecdotal reports and recent preclinical research suggest that cannabinol (CBN), a constituent of Cannabis sativa derived from delta-9-tetrahydrocannabinol, could be an effective treatment. Despite this, t...

Full description

Bibliographic Details
Main Authors: Ronald R Grunstein, Bandana Saini, Christopher J Gordon, Anastasia Suraev, Angela L D'Rozario, Chris Irwin, Camilla M Hoyos, Iain McGregor, Brendon Yee, Isobel Lavender, Danielle McCartney, Nathaniel Marshall
Format: Article
Language:English
Published: BMJ Publishing Group 2023-08-01
Series:BMJ Open
Online Access:https://bmjopen.bmj.com/content/13/8/e071148.full

Internet

https://bmjopen.bmj.com/content/13/8/e071148.full

Similar Items